Skip to content
Stetwright
Try free

Can I say it?

Can I say “same as Ozempic” in a telehealth ad?

Usually no. 6 rules fired across 3 sample sentences, and the checker's own text explains why.

The short answer

Usually no. The checker blocks the bare phrase in this setting. The first rule it hits is CG-DIS-028. Its reason: Comparing a supplement to a GLP-1 prescription drug ("natural Mounjaro", "mimics Ozempic") claims drug-like effects on weight and blood sugar and implies the product does what an approved drug does.

Source the rule cites: FDCA 201(g)(1); 21 CFR 101.93(g); FTC Act section 5; FTC Health Products Compliance Guidance

Checked as an ad promoting a clinical service. Context changes the result. The same samples hit these blocking rules: 3 in a drug or device ad, 2 in a supplement ad, 3 in a clinical service ad.

A clear result is not an all-clear. The checker flags wording for review and does not know your evidence, your state or your platform's review. Read the limitations.

Sample wording, run through the checker

These are sentences written to contain the phrase, not real claims. Each ran through the real engine and the shipped rule-set when this site was built.

Sample 1 · actual checker output6 rules fired

Same as Ozempic, but cheaper.

  • BlockingCG-DIS-028Disease claims. Matched: “Same as Ozempic”
  • BlockingCG-REG-006Regulatory status. Matched: “Same as Ozempic”
  • BlockingCG-RFA-006Regulatory status. Matched: “Ozempic, but cheaper”
  • WarningCG-PLT-011Platform policy. Matched: “Ozempic”
  • WarningCG-PLT-034Platform policy. Matched: “Ozempic”
  • WarningCG-TRI-008Regulatory status. Matched: “Same as Ozempic”
Sample 2 · actual checker output5 rules fired

Same active ingredient as Wegovy.

  • BlockingCG-REG-006Regulatory status. Matched: “Same active ingredient as Wegovy”
  • BlockingCG-RFA-006Regulatory status. Matched: “Same active ingredient as Wegovy”
  • WarningCG-PLT-011Platform policy. Matched: “Wegovy”
  • WarningCG-PLT-034Platform policy. Matched: “Wegovy”
  • WarningCG-TRI-008Regulatory status. Matched: “Same active ingredient as Wegovy”
Sample 3 · actual checker output5 rules fired

The same as Mounjaro, without the price.

  • BlockingCG-DIS-028Disease claims. Matched: “same as Mounjaro”
  • BlockingCG-REG-006Regulatory status. Matched: “same as Mounjaro”
  • WarningCG-PLT-011Platform policy. Matched: “Mounjaro”
  • WarningCG-PLT-034Platform policy. Matched: “Mounjaro”
  • WarningCG-TRI-008Regulatory status. Matched: “same as Mounjaro”

What to say instead

This version came back with no rule fired:

We offer weight management visits with a licensed clinician. Ask us what medicines we prescribe and what they are made from.

Actual checker output: no rule fired. It still has to be true for your business.

What the rules themselves suggest:

  • CG-DIS-028 Do not name or compare to a prescription drug. Describe the ingredients.
  • CG-REG-006 Say the medication is compounded, that it is not FDA approved, and that a licensed clinician decides whether it is appropriate.
  • CG-RFA-006 Do not market compounded or research peptides for weight loss, and do not claim equivalence with Ozempic, Wegovy, Mounjaro or Zepbound.

The rules behind this answer

Reason, source and citation for each rule that fired, in the checker's own words. Blocking rules come first.

  1. CG-DIS-028 · Blocks approval · Citation checked against stored text

    Comparing a supplement to a GLP-1 prescription drug ("natural Mounjaro", "mimics Ozempic") claims drug-like effects on weight and blood sugar and implies the product does what an approved drug does.

    Source: FDCA 201(g)(1); 21 CFR 101.93(g); FTC Act section 5; FTC Health Products Compliance Guidance

    Safer wording: Do not name or compare to a prescription drug. Describe the ingredients.

    21 CFR 101.93(g) · Needs counsel review

  2. CG-REG-006 · Blocks approval · Citation checked against stored text

    Compounded drugs are not FDA approved and are not the same as, or generics of, the brand product. Telehealth sellers have received FDA warning letters for these claims.

    Source: FDCA 503A and 503B; FDA warning letters to telehealth firms on compounded GLP-1 marketing; FTC Act section 5

    Safer wording: Say the medication is compounded, that it is not FDA approved, and that a licensed clinician decides whether it is appropriate.

    FDCA 503A · Needs counsel review

  3. CG-RFA-006 · Blocks approval · Citation checked against stored text

    Marketing semaglutide, tirzepatide or peptides for weight loss as research chemicals or as the same ingredient as a brand-name drug sells an unapproved new drug and implies equivalence to an approved product.

    Source: FDCA 201(g)(1); 21 CFR 101.93(g); FTC Health Products Compliance Guidance

    Safer wording: Do not market compounded or research peptides for weight loss, and do not claim equivalence with Ozempic, Wegovy, Mounjaro or Zepbound.

    21 CFR 101.93(g) · Needs counsel review

  4. CG-PLT-011 · Warns · Citation checked against stored text

    A named prescription drug in an ad triggers advance approval on most platforms. Pinterest allows prescription drug ads only with prior permission and GLP-1 ads only from approved healthcare advertisers in the US and Canada, Snap requires prescription advertisers to be pre-approved, and TikTok requires proof of regulator approval and 18+ targeting in the US. Meta requires LegitScript certification or its own review, Meta authorization, a licensed-professional disclaimer and 18+ targeting in the US, Canada or New Zealand. LinkedIn requires prior authorization, US or Canada only, no under-18 targeting. Reddit, X, Microsoft, Amazon and Nextdoor require pre-approval, a sales representative or case-by-case review, and Yahoo accepts FDA-approved prescription drug ads in the US only.

    Source: Pinterest Advertising Guidelines (healthcare products and services, weight loss products and services); Snap Ads Category Requirements, Health (prescription medicines); TikTok Healthcare and Pharmaceuticals ad policy (United States, prescription medicine); Meta Advertising Standards, Drugs and pharmaceuticals; LinkedIn Advertising Policies; X Ads healthcare policy; Reddit Ads Healthcare Products and Services policy; Microsoft Advertising Healthcare and Pharmaceutical policy; Amazon Ads Healthcare products and services policy; Nextdoor Ads Policy; Yahoo Ad Policy, Prescription drugs; Spotify Advertising Policies

    Safer wording: Get the platform's written approval first, then run the ad only on the platform that approved it, with the approved audience and age limits. Otherwise advertise the clinical service without naming the drug.

    Meta Advertising Standards, Drugs and pharmaceuticals, Nextdoor Ads Policy, Yahoo Ad Policy, Prescription drugs, Spotify Advertising Policies, Microsoft Advertising Healthcare and Pharmaceutical policy, Reddit Ads Healthcare Products and Services policy, Amazon Ads Healthcare products and services policy, TikTok Healthcare and Pharmaceuticals ad policy, Snap Ads Category Requirements, Health, Pinterest Advertising Guidelines, LinkedIn Advertising Policies, X Ads healthcare policy

  5. CG-PLT-034 · Warns · Citation checked against stored text

    Quora restricts healthcare advertising, including prescription and over the counter medication, GLP-1 medications, online and offline pharmacies, and clinical trial recruitment. These need Quora's approval before the ad runs. This is platform policy, not law, and an ad can be rejected without it.

    Source: Quora Advertising Policies ("We restrict the promotion of healthcare-related content."; "We restrict GLP-1 medications.")

    Safer wording: Ask Quora for approval with your company name, the product or service and the landing page before you run the ad. Appointment booking sites, basic medical supplies and online therapy apps do not need prior approval.

    Quora Advertising Policies

  6. CG-TRI-008 · Warns

    Presenting a compounded or unapproved GLP-1 product as the same as an FDA approved brand drug, with the same results, misstates its regulatory status and equivalence.

    Source: FDA statements on compounded GLP-1 drugs and Section 503A of the FDCA; FDA warning letters on compounded semaglutide and tirzepatide marketing; FTC Act section 5

    Safer wording: Do not call a compounded product the same as, or a generic of, the brand drug. State that compounded drugs are not FDA approved and are not reviewed for safety or efficacy.

    See source text · Needs counsel review

Background: Off-label promotion in the glossary.

Questions

Which rule covers brand-name drug comparisons?

Rule CG-DIS-028. It cites 21 CFR 101.93(g). The rule's reason: Comparing a supplement to a GLP-1 prescription drug ("natural Mounjaro", "mimics Ozempic") claims drug-like effects on weight and blood sugar and implies the product does what an approved drug does.

What should I write instead?

The rule's own suggestion for rule CG-DIS-028: Do not name or compare to a prescription drug. Describe the ingredients.

Does the answer change for a drug, a supplement or a service?

Context changes the result. The same samples hit these blocking rules: 3 in a drug or device ad, 2 in a supplement ad, 3 in a clinical service ad. Pick the type that matches what you promote when you run the checker.

Next step

Check your own wording

Paste your copy into the free checker. Every flag names its rule and its source.

Open the checkerHow it works